Disclosed is a pharmaceutical combination comprising: (i) a PDGF antagonist that is an antibody or binding fragment thereof; and (ii) a VEGF antagonist that is an aptamer; and wherein the PDGF antagonist and VEGF antagonist are formulated for sequential or simultaneous administration to a patient.